Drug Discovery World

DECEMBER 7, 2022

Data analytics company Phesi analysed 2,358 clinical trials involving collagen. In the first 10 months of 2022, there were more than 225 new trials, compared with 125 in 2012. billion by 2028. Phesi’s analysis shows that just 27% of trials received industry funding. billion USD, and is expected to grow to $16.7

Clinical Trials 130

Clinical Trials Trials Clinical Research Clinical Development 130

DrugBank

SEPTEMBER 26, 2024

Due to the less extensive clinical trial requirements and the competitive nature of the biosimilar market, these biologics can be produced and marketed at significantly lower prices than their reference counterparts. The primary advantage is cost-effectiveness.

Biosimilars 69

Biosimilars Clinical Trials FDA Production 69

The Pharma Data

JANUARY 19, 2021

The company hopes to raise $140 million of common stock, which will be used to advance its clinical and earlier stage programs and for R&D, working capital and general corporate purposes. TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is based in Suzhou and Shanghai, China.

Small Molecule 52

Small Molecule Laboratories Trials Immune Response 52

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Limited blinded tolerability data from the ongoing Phase 3 trial, confirming the mostly mild to moderate tolerability profile as was observed in Phase 1. Protease Inhibitor Program.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

NOVEMBER 8, 2020

R&D pipeline continues to drive future value through innovation and differentiated therapies including expected upcoming approval of Tirbanibulin. Almirall will initiate a Phase III trial soon to demonstrate the drug’s efficacy and safety in China. Financial highlights (€ million). .

Licensing 52

Licensing Licensing Marketing Production 52